Metastatic breast cancer trials in Chile

5 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 2/3Taking people
  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  Where

  Concepción, Iquique, Las Condes, Providencia, Santiago

  Age

  18 years and over

  People

  650 worldwide

  Run by

  Hoffmann-La Roche

  See details and how to joinNCT07413939 · EU 2025-524498-17-00
• Phase 3Taking people
  A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  Where

  Santiago, Temuco

  Age

  18 years and over

  People

  1,000 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07060807 · EU 2025-520582-51-00
• Phase 3Taking people
  Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  Where

  Providencia, Recoleta, Santiago, Talca, Viña del Mar

  Age

  18 years and over

  People

  788 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06380751 · EU 2023-504180-16-00
• Phase 1/2Taking people
  A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  Where

  Concepción, La Serena, Santiago, Temuco

  Age

  18 years and over

  People

  680 worldwide

  Run by

  Daiichi Sankyo

  See details and how to joinNCT06330064 · EU 2023-509632-26-00
• Phase 3Taking people
  A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  Where

  Antofagasta, Santiago

  Age

  18 years and over

  People

  1,200 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06312176 · EU 2023-504918-29-00